Drug Profile
Oncolysin S
Alternative Names: N901-blocked ricin; N901-BRLatest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator ImmunoGen
- Developer Dana-Farber Cancer Institute; ImmunoGen
- Class Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Small cell lung cancer
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 25 Nov 1998 Discontinued-II for Small cell lung cancer in Switzerland (Infusion)
- 25 Nov 1998 Discontinued-II for Small cell lung cancer in USA (Infusion)